Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06569212 · ClinicalTrials.gov registry record · Phase 4
Beta-1 Adrenergic Inhibition to Reduce Cardiac Injury and Inflammation After Subarachnoid Hemorrhage (BADCATS)
A Phase 4 study of Non-Traumatic Subarachnoid Hemorrhage, sponsored by Madeleine Puissant.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06569212 is a Phase 4 study of Non-Traumatic Subarachnoid Hemorrhage that is actively recruiting participants, run by Madeleine Puissant. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06569212, a Phase 4 study of Non-Traumatic Subarachnoid Hemorrhage, is actively recruiting participants, sponsored by Madeleine Puissant.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the effect of early metoprolol administration after non-traumatic subarachnoid hemorrhage (SAH).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Metoprolol
Study Locations (1)
Maine
- MaineHealth - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-09-23 |
| Est. Completion | 2029-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06569212
The ClinicalTrials.gov registry entry for NCT06569212 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Madeleine Puissant, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Traumatic Subarachnoid Hemorrhage appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06569212 reports 1 study location spanning 1 distinct geographic area - top geographies include Maine.
Frequently Asked Questions
What is clinical trial NCT06569212 about?
NCT06569212 is a clinical study titled "Beta-1 Adrenergic Inhibition to Reduce Cardiac Injury and Inflammation After Subarachnoid Hemorrhage (BADCATS)". To determine the effect of early metoprolol administration after non-traumatic subarachnoid hemorrhage (SAH).
What is the current status of trial NCT06569212?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2024-09-23. Estimated completion is 2029-09.
What conditions does trial NCT06569212 study?
This clinical trial studies the following conditions: Non-Traumatic Subarachnoid Hemorrhage.
What interventions are being tested in trial NCT06569212?
The interventions under investigation include: Placebo (DRUG), Metoprolol (DRUG).
Who is sponsoring clinical trial NCT06569212?
This trial is sponsored by Madeleine Puissant, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06569212 being conducted?
This trial has 1 study location across Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.